Please contact Diya Li at email@example.com or 202-463-5689.
In China, GIPC has a three pillar program: Advocacy, Alliance Building and Analysis. Our goal is for China to adopt a market-driven approach to innovation, harmonize with its global trading partners and keep up the pace of reform.
The U.S.-China IP Cooperation Dialogue is a collaboration between Renmin University’s China Intellectual Property Academy and the U.S. Chamber of Commerce.
A group of IP experts from the U.S. and China engage in-depth discussions on the most complex and challenging IP issues facing China and issue a report of their findings.
For a list of this year’s experts and to read previous reports, click here.
GIPC and its Chinese partner, IP Powernation, produced a ground-breaking film which captures the stories of Chinese entrepreneurs and how intellectual property was the key to their success.
An innovative pharmaceutical ecosystem makes possible the discovery of new life-saving medicines that benefit patients around the world. Policy makers are charged with creating balanced healthcare systems that ensure access to pioneering medicines and lowering the cost of medicines through the availability of generic drugs. In the United States, a “patent linkage” system created by the Hatch-Waxman Act in 1984 provides a mechanism which encourages the early introduction of generic products without comprising the patent system. This report looks at how the patent linkage system in the United State is a model for innovation.